Future of obesity medicine

Exciting times ahead for the field of obesity medicine. As a specialist working at the intersection of lifestyle change and clinical care, I’m encouraged by the next generation of therapies that are rapidly advancing from trial to potential practice.

We’re witnessing a paradigm shift: rather than just “managing” weight as a side effect of other diseases, we are now positioning obesity itself as a treatable, modifiable chronic condition.

Some of the most promising therapies in development include:

Orforglipron a once-daily, oral small-molecule GLP-1 receptor agonist currently in Phase 3 trials for adults with overweight/obesity.

Retatrutide, a novel triple-hormone agonist (GLP-1, GIP, glucagon receptors) that in 48-week Phase 2 studies achieved mean weight reductions of ~22–24%.

Mazdutide, a dual GLP-1/glucagon receptor agonist in multiple Phase 3 programs, with data showing clinically meaningful body-weight reductions.

MariTide (maridebart cafraglutide) an investigational monthly (or less frequent) injectable that in Phase 2 delivered up to ~20% average weight loss at 52 weeks.

CagriSema (cagrilintide + semaglutide) a combination therapy currently entering Phase 3 trials, with early data showing ~15% or more weight loss and potential to surpass current standards.

Why this matters:

These therapies hold the promise of clinical transformation. By more effectively reducing adiposity, improving metabolic parameters, and lowering cardiovascular risk (especially when paired with lifestyle changes), we move closer to treating obesity as a foundational driver of disease, not just a symptom.

They offer new tools for value based care models. As patients achieve durable weight loss and improved cardiometabolic health, the downstream benefits include fewer major cardiovascular events, lower incidence of type 2 diabetes, and reduced burden of metabolic disorders, all of which align with better population health and lower long-term costs.

Importantly, none of these drugs eliminate the need for behavior change, holistic lifestyle programs, and multidisciplinary support but they enhance what we can achieve in the clinic. For practices like ours, integrating cutting-edge pharmacotherapy with intensive lifestyle interventions is the future.

Finally, an oral agent (Orforglipron) and less-frequent dosing options (e.g., MariTide monthly) may improve access, acceptability, and adherence critical factors for real-world impact.

As a clinician and obesity-medicine specialist, I’m committed to staying at the forefront of translating science into care. In the months and years ahead, I believe we will see real progress not just in weight metrics, but in improved lives, better health outcomes, and meaningful cost-savings for value-based health systems.